Selvita – integrated drug discovery partner

News Archive

New whitepaper on Selvita Protein Modeling Platform

Thanks to international effort of genome sequencing projects, last years brought massive amount of new amino acid sequences. Although experimental methods for determining protein structure are providing new structures, they cannot keep the pace at which sequences are resolved. For a large fraction of proteins whose structures will not be determined experimentally, computational methods can provide valuable information.

Protein modeling in silico is a strong competency at Selvita. Our development team has extensive experience in protein modeling, structure prediction and mining of protein structure and sequence data on genomic scale. The full scope and high interoperability of our protein modeling tools makes Selvita unique among collaboration partners in the field.

We have implemented an unique protein modeling technology. Our innovative, comparative modeling strategies enable determination of high quality structures as well as protein fold recognition in more difficult cases, when standard sequence search methods have failed.

Detailed information on Selvita Protein Modeling Platform is included in the whitepaper:
Selvita Protein Modeling Platform

Selvita has released the most recent results of its SEL24 oncology program

Kraków, Poland – April 14, 2010 – Selvita has released the most recent results of its SEL24 oncology program.

In vitro and in vivo evaluation of an optimized series of compounds was performed.

Dr. Nicolas Beuzen, Selvita’s CSO commented about the results:
“In order to improve the potency and selectivity of the original compound, a series of new derivatives was synthesized and screened for Pim-1 inhibition. Among the newly synthesized compounds several exerted increased potency in Pim-1 inhibition with IC50 values below 5 nM, confirmed in biomarkers studies. Moreover, our recent in vivo experiments showed substantial tumor growth inhibition in leukemia models.”

Pim kinases are one of the most interesting new therapeutic targets which are being currently researched by the biggest pharmaceutical companies in the world. According to the most recent literature reviews Pim kinases are strongly related to the process of oncogenesis and development of leukemias, prostate cancer, breast cancer, pancreatic cancer, renal cancer and glioblastomas.

SEL24 is the major oncology program that Selvita currently has in its pipeline, first-in-human application for SEL24 is planned for 2011.

About Selvita
Selvita delivers comprehensive solutions to customers from the pharmaceutical and biotechnology industry targeted at lowering the cost of introducing innovative compounds to the market. The areas of our activity include: advanced protein modeling services and software; computer aided drug design; optimization of lead compounds; contract synthesis;
information technology for research projects. Selvita also conducts its own innovative research projects for the pharmaceuticals customers, in collaboration with various leading research institutions.
Currently projects being developed are in the area of oncology and central nervous system.

For more information about the project or the company, please contact: This e-mail address is being protected from spam bots, you need JavaScript enabled to view it

BioCentrum will perform crystallography studies for the Institute of Biotechnology and Antibiotics

BioCentrum (Selvita Group) and the Institute of Biotechnology and Antibiotics announced commencement of cooperation concerning conduction of crystallography studies as an element of preparation of the registration dossier for a medicinal product.

Institute of Biotechnology and Antibiotics as a coordinator of the consortium of several Polish academic institutions, aiming at the development of technology and conduction of preclinical studies testing the properties of recombinant human insulin analogues with a modified hypoglycaemic effect, decided to entrust BioCentrum (Selvita Group) with the crystallographic studies required to determine the spatial structure of chosen insulin analogues.

Scope of this project, includes development of methods for creation of insulin analogues crystals with the quality suitable for crystallographic measurements, tests using X-ray crystallography to determine the spatial structure of the analogues with atomic resolution, and a detailed analysis of the obtained structural models as well as for the development of a detailed documentation.

We appreciate the possibility of strengthening our cooperation with such renowned research institute as the Institute of Biotechnology and Antibiotics. We are very pleased that IBA has a high opinion of their cooperation with the Selvita Group and has trusted us with another project. We believe that the unique capabilities of our dedicated protein biochemistry and crystallography teams will provide the highest quality of work which is to be conducted in this project - said Dr. Milosz Gruca, Director of Research and Development, Board Member of BioCentrum.

Entrusting Selvita Group with this project, we’ve guaranteed ourselves services of an experienced team that has the appropriate research facilities, scientific knowledge and the ability to work in accordance with the international quality standards of R&D. With such partner by our side, who approaches the tasks in our project with competence and full commitment , we are confident that we will achieve the intended goals - said Bożena Tejchman-Małecka, Head of the Department of Chemical Analysis at the Institute of Biotechnology and Antibiotics.

The project covered by this agreement will be conducted in a way that all the results and prepared documentation will be available for direct use for the registration of a medicinal product by the entity implementing the project.

All tests performed by BioCentrum will be carried out in accordance with the regulations of the Polish and European pharmaceutical law, as well as according to the directives of the European Medicines Agency.

Selvita Group is an innovative Polish company providing research and development services and IT solutions. We deliver comprehensive solutions for pharmaceutical and research companies targeted at lowering the cost of bringing products to market. The group also includes BioCentrum, which has been audited and qualified by the General Pharmaceutical Inspectorate in the field of therapeutical substance manufacturing for the physicochemical analyses of the substances and their certification. BioCentrum’s offer includes services in chemical analysis (eg. development, validation and transfer of methods of API analysis, stability testing, dissolution profiles), protein chemistry (incl. analysis of amino acid composition and sequencing), in vitro preclinical studies (ADME) crystallography, and enzyme production.

The Institute of Biotechnology and Antibiotics (IBA) is a state-owned research and development organization established in 1985 by the Minister of Industry. The IBA operates in the health service and pharmaceutical sector. It employs 151 people, including 34 research scientists. The IBA’s mission is to conduct scientific research in biotechnology, and the development and implementation of antibiotic technology and other biologically active substances; strengthening, and improving the image and position of the IBA within the scientific communities and in the pharmaceutical sector; as well as to disseminate the quality assurance policy for IBA operations.

Media Contact:

Natalia Pawela

This e-mail address is being protected from spam bots, you need JavaScript enabled to view it

tel: +48 784 069 418

Selvita participates in the 9th World Drug Discovery & Development Summit 2010

Location: 26-27th October 2010, Scandic Hotel Copenhagen, Copenhagen, Denmark.

The 9th Annual World Drug Discovery & Development Summit is the conference and networking event for innovation in drug discovery and pre-clinical development. The 2010 programme will discuss through a mixture of strategic and scientific sessions, how the industry is dealing with threats from dwindling pipelines, generic competition and patent expiries through advances in R&D.

This multi streamed event will focus on these four key areas:

    * target identification and validation
    * lead identification and optimisation
    * Pre-clinical development
    * Informatics

Strategic areas which will be addressed in the programme are:

    * Creative ways to address unmet medical needs and business demands
    * Collaboration to enhance in-house R&D – creating profitable alliances
    * Data mining and knowledge mining for drug innovation and repositioning
    * Orphan drug discovery and development– exploiting the potential for parallel drug development
    * Using systems biology to improve decision making in drug development

If you would like to arrange a meeting with one of Selvita's delegated on this conference, please contact:
This e-mail address is being protected from spam bots, you need JavaScript enabled to view it or call at: +48 12 297 47 00.

More about WDDS 2010

Selvita participates in the ChemOutsourcing Conference and Exhibition

Place: Ocean Place Resort, 14th-16th September 2010, Long Branch, NJ, USA

The annual ChemOutsourcing Show has emerged in the past years as a uniquely useful pharmaceutical industry-specific meeting which brings benefits to everyone who attends it.

ChemOutsourcing offers a unique conference featuring over 100 speakers, mostly from pharma and biotech companies, and sessions cover the chemical gamut from discovery, pre-clinical development, and commercial scale manufacturing.

To contact a representative of Selvita at the ChemOutsourcing Conference and Exhibition, please send an e-mail to This e-mail address is being protected from spam bots, you need JavaScript enabled to view it , or call: +48 12 297 47 00.

Read more about ChemOutsourcing conference and Exhibition.

<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>